Verve Therapeutics Stock Probability of Future Stock Price Finishing Over 6.58
| VERV Stock | USD 6.58 0.30 4.36% |
Closest to current price Verve long CALL Option Payoff at Expiration
Verve |
Verve Therapeutics Target Price Odds to finish over 6.58
The tendency of Verve Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 6.58 | 90 days | 6.58 | roughly 97.0 |
Based on a normal probability distribution, the odds of Verve Therapeutics to move above the current price in 90 days from now is roughly 97.0 (This Verve Therapeutics probability density function shows the probability of Verve Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 4.17 . This entails as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Verve Therapeutics will likely underperform. Additionally Verve Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite. Verve Therapeutics Price Density |
| Price |
Predictive Modules for Verve Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Verve Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Verve Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Verve Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Verve Therapeutics is not an exception. The market had few large corrections towards the Verve Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Verve Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Verve Therapeutics within the framework of very fundamental risk indicators.α | Alpha over NYSE Composite | -0.97 | |
β | Beta against NYSE Composite | 4.17 | |
σ | Overall volatility | 2.84 | |
Ir | Information ratio | -0.11 |
Verve Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Verve Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Verve Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Verve Therapeutics generated a negative expected return over the last 90 days | |
| Verve Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 11.76 M. Net Loss for the year was (200.07 M) with loss before overhead, payroll, taxes, and interest of (128.15 M). | |
| Verve Therapeutics currently holds about 293.56 M in cash with (149.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9. | |
| Over 87.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from accesswire.com: INVESTOR ACTION ALERT The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm |
Verve Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Verve Stock often depends not only on the future outlook of the current and potential Verve Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Verve Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 64.2 M | |
| Cash And Short Term Investments | 624 M |
Verve Therapeutics Technical Analysis
Verve Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Verve Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Verve Therapeutics. In general, you should focus on analyzing Verve Stock price patterns and their correlations with different microeconomic environments and drivers.
Verve Therapeutics Predictive Forecast Models
Verve Therapeutics' time-series forecasting models is one of many Verve Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Verve Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Verve Therapeutics
Checking the ongoing alerts about Verve Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Verve Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Verve Therapeutics generated a negative expected return over the last 90 days | |
| Verve Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 11.76 M. Net Loss for the year was (200.07 M) with loss before overhead, payroll, taxes, and interest of (128.15 M). | |
| Verve Therapeutics currently holds about 293.56 M in cash with (149.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9. | |
| Over 87.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from accesswire.com: INVESTOR ACTION ALERT The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm |
Check out Verve Therapeutics Backtesting, Verve Therapeutics Valuation, Verve Therapeutics Correlation, Verve Therapeutics Hype Analysis, Verve Therapeutics Volatility, Verve Therapeutics History as well as Verve Therapeutics Performance. For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Verve Stock analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Verve Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verve Therapeutics. If investors know Verve will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verve Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.12) | Revenue Per Share 0.183 | Quarterly Revenue Growth 4.083 | Return On Assets (0.19) | Return On Equity (0.35) |
The market value of Verve Therapeutics is measured differently than its book value, which is the value of Verve that is recorded on the company's balance sheet. Investors also form their own opinion of Verve Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Verve Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verve Therapeutics' market value can be influenced by many factors that don't directly affect Verve Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verve Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verve Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verve Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.